Post Approval changes

STRONG EVIDENCE OF VALUE, EFFECTIVENESS, AND SAFETY IS ESSENTIAL FOR OPTIMIZING PATIENT ACCESS.

The magnitude of evidence required by biopharmaceutical companies to demonstrate value and efficacy in post-approval settings is increasing, as is the means of presenting this evidence to payers, health authorities, and other decision-makers.

Is the treatment safe in the real world and does it improve patient outcomes?

Which patients will gain the most from the course of care?

Does the treatment offer good value for the money and is it worth the cost?

0 +

Peer-reviewed publications per year

0 +

Global payer submissions supported per year

0 +

Therapies per year where KLCRO has helped generate evidence to demonstrate safety, effectiveness and value

INFLUENCE

INFLUENCE Developed evidence to reverse, fast-track and influence National Institute for Clinical Excellence (NICE) decisions across a variety of therapeutic areas

“Trusted Partner”

Navigating the dynamic landscape of drug development poses challenges as patient engagement rises and real-world data sources evolve. With shifting stakeholder and regulatory landscapes, complexity amplifies. That’s where a trusted partner comes in, providing clarity and guidance amidst the chaos, ensuring patients receive the necessary treatments.